PND-1186 (CAT: I000311) is a potent FAK (focal adhesion kinase) inhibitor that has been developed as an anti-tumor drug for cancer therapy. In vitro studies have shown that PND-1186 inhibits FAK phosphorylation, leading to the inhibition of cell movement and the promotion of cell apoptosis in breast carcinoma cells. It has demonstrated limited effects on cell proliferation but has shown efficacy in blocking tumor growth and metastasis in vivo. PND-1186 has been well-tolerated in preclinical studies, and clinical trials are being conducted to evaluate its safety and efficacy in patients with metastatic non-hematological malignancies.
Catalog Number | I000311 |
CAS Number | 1061353-68-1 |
Synonyms | 2-((2-((2-methoxy-4-morpholinophenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)-N-methylbenzamide |
Molecular Formula | C25H26F3N5O3 |
Purity | ≥95% |
Target | FAK |
Solubility | DMSO: ≥ 34 mg/mL |
Storage | Store at -20°C |
Overview of Clinical Research | <p> |
IC50 | 1.5 nM |
IUPAC Name | 2-[[2-(2-methoxy-4-morpholin-4-ylanilino)-5-(trifluoromethyl)pyridin-4-yl]amino]-N-methylbenzamide |
InChI | InChI=1S/C25H26F3N5O3/c1-29-24(34)17-5-3-4-6-19(17)31-21-14-23(30-15-18(21)25(26,27)28)32-20-8-7-16(13-22(20)35-2)33-9-11-36-12-10-33/h3-8,13-15H,9-12H2,1-2H3,(H,29,34)(H2,30,31,32) |
InChIKey | IGUBBWJDMLCRIK-UHFFFAOYSA-N |
SMILES | CNC(=O)C1=CC=CC=C1NC2=CC(=NC=C2C(F)(F)F)NC3=C(C=C(C=C3)N4CCOCC4)OC |
Reference | <br /> |